Pace Life Sciences Announces Compliant US FDA Inspection Of Operations In Oakdale, MN

Proven track record of consistent high quality confirmed at Pace Life Sciences headquarters

Pace Life Sciences, a full-service FDA-registered GMP Analytical Testing laboratory and contract development and manufacturing organization (CDMO) and a Division of Pace, a Science and Technology Company, announced today a successful inspection from The Food & Drug Administration (FDA).

Lou Forcellini, Head of Quality Assurance at Pace Life Sciences shared, "The latest successful inspection of our Oakdale central laboratory further underscores our steadfast quality leadership, the expertise of our laboratory professionals, and our commitment to data integrity and compliance through robust quality systems. I am extremely proud of the teams that work hard every day to ensure these successes." Earlier this year, the Pace Life Sciences laboratory in San German, Puerto Rico, also was inspected by the FDA. Favorable outcomes from that inspection of the harmonized quality systems shared between the sites further demonstrate compliance and the company's dedication to consistently providing quality results to clients.

Serving pharmaceutical and biopharmaceutical manufacturers for over 15 years, the 60,000 ft2 Oakdale location has been at the forefront of testing gene therapies and many other life-changing drugs. Supporting clients from early-stage research and development to commercialization, the Oakdale facility offers a wide range of commercial product release and stability testing for raw materials, active pharmaceutical ingredients, finished pharmaceuticals, and biologics. Top pharmaceutical companies work with Pace as their trusted partner for analytical development and GMP Analytical Testing.

Pace is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.